A look at the biologics, gene therapies, and vaccines most likely to reshape care —and manufacturing—in the year ahead.

AxoGen (NASDAQ:AXGN) used its presentation at the 47th annual Raymond James Institutional Investors Conference to outline its mission to make restoration of peripheral nerve function an expected ...

In the release, the first paragraph of the Fourth Quarter and Full Year 2025 Financial Results section, second sentence should read: Net loss per common share was $0.76 for the quarter ended December ...

Real Madrid will be aiming to bounce back to winning ways in La Liga when they face Celta Vigo away at Balaidos on Friday ...

The summer transfer window is drawing closer and rumours are intensifying. It is no surprise that top clubs like FC Barcelona ...

Ocugen maintains its guidance to submit a rolling Biologics License Application (BLA) for OCU400 in the third quarter of 2026. A rolling submission allows the company to present completed sections of ...

ImmunityBio has delivered compelling evidence that its flagship therapy, ANKTIVA, is achieving significant commercial traction. While regulatory approvals in Europe and robust clinical data have ...

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational. If approved, it has the potential to be the first ophthalmic formulation of bevacizumab-vikg approved by the FDA for use ...

MELBOURNE, Australia and INDIANAPOLIS, March 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) invites investors to join a webinar with key opinion leaders to ...

One of the highest profile players at Liverpool has 'the worst record of any Premier League player' in his position this season, and the Reds might be wise to cash in while they can with two Euro ...